Improving diversity in future clinical trials for mHSPC

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

EP: 4.The current treatment landscape of mHSPC

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

Now Viewing

EP: 11.Improving diversity in future clinical trials for mHSPC

EP: 12.Remaining unmet needs in diverse populations with mHSPC

Improving Clinical Trial Diversity

Key Themes:

• A multistakeholder approach is required (patients, communities, clinicians, payers, industry).
• Community outreach initiatives are essential for building trust.
• A comprehensive approach is needed to address the barriers to participation.
• Bring clinical trial access directly into communities of color.

Key Points for Physicians:

• Support or participate in community outreach programs.
• Address practical barriers to clinical trial participation with patients.
• Consider geographical and logistical factors when referring patients to trials.
• Recognize the importance of building trust through community engagement.

Notable Insights: Creating direct conduits to high-quality care through community-based initiatives represents a practical strategy for improving trial diversity and addressing historical mistrust.

Clinical Significance: Systematic approaches to improving trial diversity are essential for generating evidence applicable to all patient populations and addressing historical health care disparities.